<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02775539</url>
  </required_header>
  <id_info>
    <org_study_id>SPHERE-HF</org_study_id>
    <nct_id>NCT02775539</nct_id>
  </id_info>
  <brief_title>Beta3 Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure</brief_title>
  <acronym>SPHERE-HF</acronym>
  <official_title>Beta3 Adrenergic Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario 12 de Octubre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Puerta de Hierro University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of mirabegron (a B3
      adrenergic receptor agonist) in patients with pulmonary hypertension secondary to heart
      failure by conducting a randomized multicenter phase II placebo-controlled clinical trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pulmonary hypertension (PH) affects 60-80% of patients with chronic heart failure (HF) and
      has a critical impact on prognosis. Currently, there is no specific treatment approved for
      this indication. Experimental research, performed by members of the consortium, demonstrates
      that treatment with B3 adrenergic receptor agonists produces a beneficial effect on pulmonary
      hemodynamics, right ventricular (RV) remodeling and pulmonary vascular proliferation in a
      translational pig model of postcapillary PH. Mirabegron, an oral B3AR agonist, is currently
      approved for a different medical condition (overactive bladder syndrome) with a good safety
      profile. Our main objective is to evaluate the efficacy and safety of mirabegron in patients
      with PH secondary to HF.

      The objective will be evaluated by conducting a phase-2 randomized placebo-controlled
      clinical trial in patients with PH associated to HF. Patients will be randomized 1:1 to
      mirabegron or placebo, and dose will be titrated till 200 mg/day. Patients will be evaluated
      with quality of life questionnaire, blood analysis, ECG, echocardiography, 6-minute walking
      test, right heart catheterization (RHC) and cardiac magnetic resonance (CMR) at baseline and
      after 16 weeks of treatment.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in pulmonary vascular resistance (PVR) from baseline to week 16 assessed by right heart catheterization (RHC).</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in 6-minute walking distance</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in NYHA functional class</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in quality of life</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in dyspnea Borg score</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean PAP as assessed by RHC</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in cardiac index (CI) as assessed by RHC and cardiac magnetic resonance (CMR)</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in RV ejection fraction as assessed by CMR</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in BNP/NT-proBNP</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital admissions due to worsening cardiopulmonary status</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urgent heart transplantation</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New onset arrhythmia</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for initiation of intravenous therapy due to worsening HF</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse drug effects</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Pulmonary Hypertension</condition>
  <condition>Mirabegron</condition>
  <condition>Heart Failure</condition>
  <condition>Pulmonary Vascular Resistance Abnormality</condition>
  <arm_group>
    <arm_group_label>Mirabegron</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral mirabegron, starting with 50 mg once a day and titrated till a maximum of 200 mg once a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral placebo, similarly titrated to ensure blindness.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirabegron</intervention_name>
    <description>Patients will receive 50 to 200 mg of mirabegron once a day during 16 weeks. Dose will be titrated during the first 8 weeks.</description>
    <arm_group_label>Mirabegron</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written inform consent;

          -  &gt;18 years-old;

          -  HF with reduced or preserved ejection fraction, according to the definition of the
             European Society of Cardiology guidelines.

          -  Severe PH and/or combined postcapillary and precapillary PH (also knows as reactive or
             out-of-proportion PH) determined by RHC showing the following:

               -  Pulmonary arterial wedge pressure or end-diastolic left ventricular pressures ≥15
                  mmHg;

               -  Mean PAP≥25, and:

               -  PVR≥3 UW and/or diastolic gradient≥7 mmHg or

               -  Transpulmonary gradient≥12.

          -  NYHA functional class II-IV;

          -  On optimized evidence-based pharmacological treatment;

          -  Stable clinical condition defined as no changes in therapeutic regimen or
             hospitalization in the 30 days preceding recruitment and no current plan for changing
             therapy.

        Exclusion Criteria:

          -  Non-coronary cardiac surgery or non-coronary percutaneous procedure within the 12
             months preceding recruitment or programmed;

          -  Myocardial infarction or coronary revascularization during the last 3 months,

          -  Myocardial resynchronization therapy initiated during the last 6 months;

          -  Sinus tachycardia or atrial fibrillation with uncontrolled heart rate (&gt;100 bpm);

          -  Uncontrolled hypertension (PAS&gt;180 or PAD&gt;110 mmHg) or symptomatic hypotension (PAS&lt;90
             mmHg).

          -  Infiltrative myocardial disease.

          -  Expected survival &lt;1 year due to a disease other than PH;

          -  Severe renal failure (GFR &lt;30 mL/min/1.73 m2 or haemodialysis);

          -  Severe hepatic impairment (serum aspartate aminotransferase (AST) and/or alanine
             aminotransferase (ALT) &gt;3x the upper limit of normality at screening;

          -  cQT interval on the ECG &gt;430 ms in male or &gt;450 ms in female;

          -  Concomitant use of specific pulmonary vasodilator therapy (i.e. endothelin receptor
             antagonists, phosphodiesterase -5 inhibitors, guanylate cyclase stimulators).

          -  Concomitant use of digoxin, flecainide, propafenone, dabigatran, tricycle
             antidepressants, or another strong inhibitors of CYP2D6 (with the exception of
             betablockers).

          -  Significant obstructive lung disease (FEV1/FVC&lt;0.7 associated with FEV1&lt;50% of
             predicted value).

          -  Significant restrictive lung disease (TLC&lt;60%).

          -  Participation in another clinical trial.

          -  Female with childbearing potential.

          -  Known hypersensitivity to mirabegron or to any of its excipients.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ana García-Álvarez, MD, PhD</last_name>
    <phone>003491 4531200</phone>
    <phone_ext>1507</phone_ext>
    <email>anagarci@clinic.ub.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Borja Ibañez, MD, PhD</last_name>
    <phone>003491 4531200</phone>
    <phone_ext>1507</phone_ext>
    <email>bibanez@cnic.es</email>
  </overall_contact_backup>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2016</study_first_submitted>
  <study_first_submitted_qc>May 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2016</study_first_posted>
  <last_update_submitted>May 16, 2016</last_update_submitted>
  <last_update_submitted_qc>May 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary hypertension</keyword>
  <keyword>Mirabegron</keyword>
  <keyword>Heart failure</keyword>
  <keyword>B3 adrenergic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mirabegron</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

